Whether CHMP5 also regulates AML, in which the BRD4-dependent MYC super-enhancer is also a therapeutic vulnerability52,86, and other cancers that display a p300-BRD4 dependency remains to be determined. This evidence concerns the gene BRD4 and acute myeloid leukemia.